Apimeds Total Current Assets from 2010 to 2025
| APUS Stock | 1.76 0.03 1.73% |
Total Current Assets | First Reported 2010-12-31 | Previous Quarter 13.1 K | Current Value 12.4 K | Quarterly Volatility 95.7 K |
Check Apimeds Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apimeds Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 123.6 K, Selling General Administrative of 749.4 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Apimeds financial statements analysis is a perfect complement when working with Apimeds Pharmaceuticals Valuation or Volatility modules.
Apimeds | Total Current Assets | Build AI portfolio with Apimeds Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.